- Metastatic urothelial carcinoma
-
The following considers the results of Chemotherapy on Metastatic urothelial carcinoma.
"Patients with refractory advanced or metastatic urothelial carcinoma derive only minor benefit from chemotherapy".[1]
Various studies have shown combination chemotherapy to have an effect. Treatment with chemotherapy and "infusion cisplatin and high-dose 5-fluorouracil/leucovorin (P-HDFL)" results in a median survival of 38 months.[2]
Donald Kaufman worked on a study using a combination of gemcitabine and cisplatin, which resulted in a median survival of 14.3 months.[3]
Generally speaking, treatment with chemotherapy will not with any amount of certainty, extend one's life.
References
- ^ Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ (2003). "Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study". Urol. Oncol. 21 (1): 21–6. PMID 12684123. http://linkinghub.elsevier.com/retrieve/pii/S1078143902002077.
- ^ Lin CC, Hsu CH, Huang CY, et al. (March 2007). "Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens". Urology 69 (3): 479–84. doi:10.1016/j.urology.2006.12.010. PMID 17382149. http://linkinghub.elsevier.com/retrieve/pii/S0090-4295(06)02634-3.
- ^ Kaufman D, Raghavan D, Carducci M, et al. (May 2000). "Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer". J. Clin. Oncol. 18 (9): 1921–7. PMID 10784633. http://www.jco.org/cgi/pmidlookup?view=long&pmid=10784633.
Tumors: urogenital neoplasia: urinary organs (C64–C68/D30, 188–189/223) Abdominal KidneyGlandular and epithelial neoplasm: Renal cell carcinoma · Renal oncocytomaUreterPelvic Retroperitoneum Categories:- Urological neoplasia
Wikimedia Foundation. 2010.